Development of an in vitro model to study the impact of BMP-2 on metastasis to bone

Journal of Tissue Engineering and Regenerative Medicine

Volumn 4, Issue 8, 2010, Pages 590-599

  Kwon, Heenam ^a   Kim, Hyeon Joo ^a   Rice, William L ^a   Subramanian, Balajikarthick ^a   Park, Sang Hyug ^a   Georgakoudi, Irene ^a   Kaplan, David L ^a  

^a Tufts University   (United States)

Author keywords

BMP 2; cancer; metastasis; PC3; prostate; silk

Indexed keywords

BIOMATERIALS; BONE; DIAGNOSIS; PATHOLOGY; SCAFFOLDS (BIOLOGY); SILK; UROLOGY;

BMP-2; BONE METASTASIS; CANCER METASTASIS; CULTURE CONDITIONS; IN-VITRO; IN-VITRO MODELS; PROSTATE CANCER CELLS; PROSTATE CANCERS; SILK; SILK SCAFFOLD;

DISEASES;

BIOMATERIAL; BONE MORPHOGENETIC PROTEIN 2; SILK SCAFFOLD; TISSUE SCAFFOLD; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; CANCER GROWTH; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 78649644931     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.268     Document Type: Article

References (47)

1. Altman GH, Diaz F, Jakuba C, et al., 2003; Silk-based biomaterials. Biomaterials 24 (3): 401-416.
2. Armstrong AP, Miller RE, Jones JC, et al., 2008; RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate, 68 (1): 92-104.
3. Bobinac D, Maric I, Zoricic S, et al., 2005; Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat Med J 46 (3): 389-396.
4. Bonkhoff H, Stein U, Welter C, et al., 1995; Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol 26 (8): 824-828.
5. Brubaker KD, Corey E, Brown LG, et al., 2004; Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 91 (1): 151-160.
6. Cheung CP, Yu S, Wong KB, et al., 2005; Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues. J Clin Endocrinol Metab 90 (3): 1830-1844.
7. Feeley BT, Gamradt SC, Hsu WK, et al., 2005; Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20 (12): 2189-2199.
8. Feeley BT, Krenek L, Liu N, et al., 2006; Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38 (2): 154-166.
9. Groppe J, Greenwald J, Wiater E, et al., 2002; Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420 (6916): 636-642.
10. Hall CL, Bafico A, Dai J, et al., 2005; Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65 (17): 7554-7560.
11. Hall CL, Kang S, MacDougald OA, et al., 2006; Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97 (4): 661-672.
12. Hall CL, Keller ET,. 2006; The role of Wnts in bone metastases. Cancer Metast Rev 25 (4): 551-558.
13. Hogan BL,. 1996; Bone morphogenetic proteins in development. Curr Opin Genet Dev 6 (4): 432-438.
14. Ide H, Yoshida T, Matsumoto N, et al., 1997; Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57 (22): 5022-5027.
15. Jemal A, Siegel R, Ward E, et al., 2008; Cancer statistics. CA Cancer J Clin 58 (2): 71-96.
16. Karageorgiou V, Meinel L, Hofmann S, et al., 2004; Bone morphogenetic protein-2 decorated silk fibroin films induce osteogenic differentiation of human bone marrow stromal cells. J Biomed Mater Res A 71 (3): 528-537.
17. Karageorgiou V, Tomkins M, Fajardo R, et al., 2006; Porous silk fibroin 3D scaffolds for delivery of bone morphogenetic protein-2 in vitro and in vivo. J Biomed Mater Res A 78 (2): 324-334.
18. Kim HJ, Kim UJ, Leisk GG, et al., 2007; Bone regeneration on macroporous aqueous-derived silk 3D scaffolds. Macromol Biosci 7 (5): 643-655.
19. Kim HJ, Kim UJ, Vunjak-Novakovic G, et al., 2005; Influence of macroporous protein scaffolds on bone tissue engineering from bone marrow stem cells. Biomaterials 26 (21): 4442-4452.
20. Kim JB, Stein R, O'Hare MJ,. 2004; Three-dimensional in vitro tissue culture models of breast cancer - a review. Breast Cancer Res Treat 85 (3): 281-291.
21. Kim UJ, Park J, Kim HJ, et al., 2005; Three-dimensional aqueous-derived biomaterial scaffolds from silk fibroin. Biomaterials 26 (15): 2775-2785.
22. Koeneman KS, Yeung F, Chung LW,. 1999; Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39 (4): 246-261.
23. Li ZG, Yang J, Vazquez ES, et al., 2008; Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27 (5): 596-603.
24. Logothetis CJ, Lin SH,. 2005; Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5 (1): 21-28.
25. Madigan MC, Kingsley EA, Cozzi PJ, et al., 2008; The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 57 (9): 1367-1379.
26. Mastro AM, Vogler EA,. 2009; A three-dimensional osteogenic tissue model for the study of metastatic tumor cell interactions with bone. Cancer Res 69 (10): 4097-4100.
27. Moreau JE, Anderson K, Mauney JR, et al., 2007; Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res 67 (21): 10304-10308.
28. Mori K, Le Goff B, Charrier C, et al., 2007; DU145 human prostate cancer cells express functional receptor activator of NFκB: new insights in the prostate cancer bone metastasis process. Bone 40 (4): 981-990.
29. Moro L, Arbini AA, Yao JL, et al., 2008; Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. Cancer Sci 99 (3): 553-563.
30. Morrissey C, Vessella RL,. 2007; The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 101 (4): 873-886.
31. Nabha SM, dos Santos EB, Yamamoto HA, et al., 2008; Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer 122 (11): 2482-2490.
32. Nemeth JA, Harb JF, Barroso U Jr, et al., 1999; Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 59 (8): 1987-1993.
33. Nemeth JA, Yousif R, Herzog M, et al., 2002; Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94 (1): 17-25.
34. Sato S, Futakuchi M, Ogawa K, et al., 2008; Transforming growth factor-β derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci 99 (2): 316-323.
35. Schwaninger R, Rentsch CA, Wetterwald A, et al., 2007; Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol 170 (1): 160-175.
36. Singh AS, Figg WD,. 2005; In vivo models of prostate cancer metastasis to bone. J Urol 174 (3): 820-826.
37. Singh AS, Macpherson GR, Price DK, et al., 2006; Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis. Oncol Rep 15 (3): 519-524.
38. Sofia S, McCarthy MB, Gronowicz G, et al., 2001; Functionalized silk-based biomaterials for bone formation. J Biomed Mater Res 54 (1): 139-148.
39. Wang X, Wenk E, Zhang X, et al., 2009; Growth factor gradients via microsphere delivery in biopolymer scaffolds for osteochondral tissue engineering. J Control Release 134 (2): 81-90.
40. Wang Y, Kim HJ, Vunjak-Novakovic G, et al., 2006; Stem cell-based tissue engineering with silk biomaterials. Biomaterials 27 (36): 6064-6082.
41. Wang Y, Volloch V, Pindrus MA, et al., 2007; Murine osteoblasts regulate mesenchymal stem cells via WNT and cadherin pathways: mechanism depends on cell-cell contact mode. J Tissue Eng Regen Med 1 (1): 39-50.
42. Wozney JM,. 1992; The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 32 (2): 160-167.
43. Yamaguchi A, Katagiri T, Ikeda T, et al., 1991; Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol 113 (3): 681-687.
44. Yoneda T, Hiraga T,. 2005; Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328 (3): 679-687.
45. Yonou H, Yokose T, Kamijo T, et al., 2001; Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 61 (5): 2177-2182.
46. Zhang J, Dai J, Qi Y, et al., 2001; Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107 (10): 1235-1244.
47. Zhu H, Mazor M, Kawano Y, et al., 2004; Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res 64 (21): 7918-7926.